On October 3, 2019, Novelion Therapeutics Inc. announced that it will held the annual general meeting on November 5, 2019 for the purposes: to approve a special resolution: (i) the voluntary liquidation and dissolution of the Company pursuant to the Business Corporations Act (British Columbia) (the BCBCA) at a time to be determined by the board of directors of the Company; (ii) the plan of liquidation and distribution substantially in the form attached to the accompanying Proxy Statement as Schedule A; and (iii) one or more distributions to shareholders of any remaining property of the Company under the voluntary liquidation and dissolution each as more particularly described in the accompanying Proxy Statement. Further, the Company added that the Board has unanimously approved each of the proposals and recommends to vote for the Liquidation Resolution.